LEXIVA was co-discovered by GlaxoSmithKline.

LEXIVA was co-discovered by GlaxoSmithKline and Intersection Pharmaceuticals Incorporated. It is the low PI to whirl flexible dosing options (for PI-naïve patients) with no food or piddle restrictions.


The new prescribing accumulation includes data from piece of music APV10031, a randomized, open-label, cross-over composition in 48 healthy adults. Subjects received 20 mg of esomeprazole alone for heptad days followed by the indefinite quantity of 1400 mg LEXIVA BID (twice-a-day) or 700 mg LEXIVA boosted with 100 mg ritonavir (r) BID for 14 days at the same time with their dose of esomeprazole. This was followed by a 21- to 28-day channel time interval and then participants were given unboosted or boosted LEXIVA for 14 days. Results indicated that descent levels of LEXIVA were not changed when taken simultaneously with esomeprazole compared to LEXIVA administered without esomeprazole. Bodily fluid levels of esomeprazole were increased by 55 percent when taken with 1400 mg LEXIVA BID.


Proton pump inhibitors such as esomeprazole reduce levels of appetite acid and are used to nourishment several body part problems including heartburn. Over-the-counter antacids, also reduce levels of venter acid and, when co-administered with LEXIVA, did not significantly affect the ancestry levels of LEXIVA.